跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
USP1 Inhibitor
首页
药物
USP1 Inhibitor
USP1 Inhibitor
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
USP1 OR UAF1 INHIBITORS FOR USE IN TREATING CANCER
申请人: DANA FARBER CANCER INST INC
优先权: 2017
EP
US
WO
7 件公开
TRICYCLIC UBIQUITIN SPECIFIC PROTEASE 1 INHIBITOR AND USE THEREOF
申请人: SHANDONG XUANZHU PHARMA CO LTD
优先权: 2021
CN
EP
US
WO
4 件公开
PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF
申请人: JIANGSU YAHONG MEDITECH CO LTD
优先权: 2022
CN
EP
US
4 件公开
THERAPEUTIC COMBINATIONS COMPRISING UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS AND PARP1-SELECTIVE INHIBITORS
申请人: KSQ THERAPEUTICS INC
优先权: 2022
CN
EP
WO
3 件公开
PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
申请人: JIANGSU YAHONG MEDITECH CO LTD
优先权: 2023
CN
EP
WO
3 件公开
Inhibitor of ATR kinase for use in a method of treating a hyper-proliferative disease
申请人: BAYER AG
优先权: 2017
CN
US
2 件公开
TRICYCLIC USP1 INHIBITOR AND USE THEREOF
申请人: SHANDONG XUANZHU PHARMA CO LTD
优先权: 2021
CN
WO
2 件公开
THERAPEUTIC COMBINATIONS COMPRISING UBIQUITIN- SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS AND CHEMOTHERAPY AGENTS
申请人: KSQ THERAPEUTICS INC
优先权: 2022
CN
US
2 件公开
USP1 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF
申请人: CHENGDU CHIPSCREEN PHARMACEUTICAL LTD
优先权: 2024
CN
WO
2 件公开
HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF
申请人: SHANGHAI INST MATERIA MEDICA CAS
优先权: 2024
CN
WO
2 件公开
第 1 / 5 页
上一页
下一页
药物
反馈